Join our daily newsletter At The Bell to receive exclusive market insights
- Palla Pharma (PAL) has appointed Giles Moss to the role of Chief Executive Officer of the company, effective from September 2021
- The appointment comes with a £295,000 per annum salary (roughly A$536,000), with a long-term incentive of over eight million share appreciation rights
- Giles Moss comes from GW Pharmaceuticals, where he currently holds the role of Vice President and General Manager Europe
- Palla Pharma shares are up 11.1 per cent, trading at 40 cents
Palla Pharma (PAL) has appointed a new Chief Executive Officer of the company, effective from September 1, 2021.
Giles Moss has been appointed to the role, following over 30 years of commercial leadership and operational experience in the pharmaceutical industry.
The appointment comes with a £295,000 per annum salary (roughly A$536,000), and the opportunity to earn between 50 and 75 per cent of the total remuneration package for FY2021, conditional upon performance targets.
The company will also grant a long-term incentive of over eight million share appreciation rights, equal to five per cent of the total underlying share capital of the company.
He currently holds the role of Vice President and General Manager Europe at GW Pharmaceuticals, where he played a pivotal role in launching a new highly regulated orphan medicine for epilepsy.
“I am looking forward to the opportunity to lead Palla Pharma at this pivotal time,” said Giles Moss.
“Palla is well placed to meet the need for essential opioid-based pain relief products in both the established markets of Europe and the United Kingdom and also those regions where pain relief is in short supply.”
Palla Pharma shares are up 11.1 per cent, trading at 40 cents at 1:30 pm AEST.
